HRP20031091B1 - Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands - Google Patents

Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands

Info

Publication number
HRP20031091B1
HRP20031091B1 HRP20031091AA HRP20031091A HRP20031091B1 HR P20031091 B1 HRP20031091 B1 HR P20031091B1 HR P20031091A A HRP20031091A A HR P20031091AA HR P20031091 A HRP20031091 A HR P20031091A HR P20031091 B1 HRP20031091 B1 HR P20031091B1
Authority
HR
Croatia
Prior art keywords
group
branched
straight
atom
alkyl
Prior art date
Application number
HRP20031091AA
Other languages
English (en)
Croatian (hr)
Inventor
Ar�nyi P�ter
Bal�zs L�szl�
Balogh M�ria
Bata Imre
Btori Sndor
T. Nagy Lajos
T�m�ri G�za
Bo�r Kinga
Finance Olivier
Kapui Zolt�n
Mikus Endre
Szamosv�lgyi Zsuzsanna
Szeleczky Gbor
Urb�n-Szab� Katalin
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0102279A external-priority patent/HUP0102279A3/hu
Priority claimed from HU0200774A external-priority patent/HUP0200774A2/hu
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of HRP20031091A2 publication Critical patent/HRP20031091A2/xx
Publication of HRP20031091B1 publication Critical patent/HRP20031091B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
HRP20031091AA 2001-05-31 2002-05-29 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands HRP20031091B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0102279A HUP0102279A3 (en) 2001-05-31 2001-05-31 A3 antagonist amino-quinoline-derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HU0200774A HUP0200774A2 (hu) 2002-03-01 2002-03-01 Amino-piridin és amino-kinolin származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik
PCT/HU2002/000048 WO2002096879A1 (en) 2001-05-31 2002-05-29 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands

Publications (2)

Publication Number Publication Date
HRP20031091A2 HRP20031091A2 (en) 2005-10-31
HRP20031091B1 true HRP20031091B1 (en) 2012-05-31

Family

ID=47711452

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20031091AA HRP20031091B1 (en) 2001-05-31 2002-05-29 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands

Country Status (27)

Country Link
US (1) US6969723B2 (enExample)
EP (1) EP1390349B1 (enExample)
JP (1) JP4409935B2 (enExample)
KR (1) KR100745307B1 (enExample)
CN (1) CN1257160C (enExample)
AR (1) AR036074A1 (enExample)
AU (1) AU2002304358B2 (enExample)
BG (1) BG108477A (enExample)
BR (1) BR0209719A (enExample)
CA (1) CA2448561C (enExample)
CO (1) CO5550457A2 (enExample)
CZ (1) CZ20033510A3 (enExample)
EA (1) EA006854B1 (enExample)
EE (1) EE05304B1 (enExample)
HR (1) HRP20031091B1 (enExample)
IL (1) IL158854A0 (enExample)
IS (1) IS2773B (enExample)
MA (1) MA26236A1 (enExample)
MX (1) MXPA03010870A (enExample)
NO (1) NO327710B1 (enExample)
NZ (1) NZ529966A (enExample)
PL (1) PL366516A1 (enExample)
RS (1) RS95003A (enExample)
RU (1) RU2278112C2 (enExample)
SK (1) SK14142003A3 (enExample)
TN (1) TNSN03117A1 (enExample)
WO (1) WO2002096879A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
CA2508165C (en) 2002-12-06 2014-05-06 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
JP2007500689A (ja) * 2003-07-31 2007-01-18 サノフイ−アベンテイス アミノキノリン誘導体およびアデノシンａ３リガンドとしてのそれらの使用
RU2317290C2 (ru) * 2003-07-31 2008-02-20 Санофи-Авентис Производные аминохинолина и их применение в качестве лигандов аденозина а3
HUP0400812A2 (en) * 2004-04-19 2006-02-28 Sanofi Aventis Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
HUP0402371A2 (en) * 2004-11-15 2006-09-28 Sanofi Aventis Novel 125-i-labeled amino-quinoline derivatives
KR100788161B1 (ko) * 2006-01-06 2007-12-21 (주)아모레퍼시픽 벤즈이미다졸 아민 유도체 또는 아미노퀴놀린 유도체를 함유하는 피부 미백용 조성물
HUP0700395A2 (en) * 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
KR101106050B1 (ko) * 2009-03-25 2012-01-18 한국과학기술연구원 아미노퀴놀린 화합물, 이의 제조 방법 및 이를 함유하는 의약 조성물
WO2012030918A1 (en) * 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
WO2012166654A1 (en) * 2011-05-27 2012-12-06 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
CA2754237A1 (en) 2011-05-27 2012-11-27 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
CN108137547B (zh) 2015-08-03 2021-11-12 百时美施贵宝公司 可用作TNFα调节剂的杂环化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011244A1 (en) * 1993-10-22 1995-04-27 Zeneca Limited Pyridazino quinoline compounds
EP1180518A1 (en) * 1999-04-23 2002-02-20 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE265143C (enExample)
FR2582514B1 (fr) * 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
JPH01180518A (ja) * 1988-01-12 1989-07-18 Nissan Chem Ind Ltd 配向処理剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011244A1 (en) * 1993-10-22 1995-04-27 Zeneca Limited Pyridazino quinoline compounds
EP1180518A1 (en) * 1999-04-23 2002-02-20 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof

Also Published As

Publication number Publication date
US20040186133A1 (en) 2004-09-23
EE05304B1 (et) 2010-06-15
NZ529966A (en) 2004-11-26
AU2002304358B2 (en) 2007-08-23
KR20040030648A (ko) 2004-04-09
WO2002096879A1 (en) 2002-12-05
TNSN03117A1 (en) 2005-12-23
JP4409935B2 (ja) 2010-02-03
CO5550457A2 (es) 2005-08-31
EP1390349A1 (en) 2004-02-25
CN1257160C (zh) 2006-05-24
CZ20033510A3 (cs) 2005-01-12
JP2004536074A (ja) 2004-12-02
WO2002096879A9 (en) 2003-11-20
IL158854A0 (en) 2004-05-12
MXPA03010870A (es) 2004-02-27
BR0209719A (pt) 2004-07-27
MA26236A1 (fr) 2004-08-01
BG108477A (bg) 2005-01-31
RU2003137836A (ru) 2005-05-27
HRP20031091A2 (en) 2005-10-31
CN1512985A (zh) 2004-07-14
SK14142003A3 (sk) 2005-03-04
EA006854B1 (ru) 2006-04-28
NO327710B1 (no) 2009-09-14
AR036074A1 (es) 2004-08-11
EA200301317A1 (ru) 2004-06-24
RU2278112C2 (ru) 2006-06-20
EE200300574A (et) 2004-02-16
IS2773B (is) 2012-01-15
US6969723B2 (en) 2005-11-29
CA2448561A1 (en) 2002-12-05
EP1390349B1 (en) 2012-07-25
RS95003A (sr) 2007-02-05
KR100745307B1 (ko) 2007-08-01
NO20035300D0 (no) 2003-11-28
PL366516A1 (en) 2005-02-07
CA2448561C (en) 2011-07-19
IS7052A (is) 2003-11-26

Similar Documents

Publication Publication Date Title
AU651986B2 (en) Pyrazolo{1,5-a}pyrimidine derivative and anti-inflammatory containing the same
HRP20000854B1 (en) Therapeutic biaryl derivatives
PT1140916E (pt) Acetais heteroarilo ciclicos
EA200100755A1 (ru) 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
HRP20040429B1 (hr) Derivati sulfonamida, njihova priprema i upotrebakao lijekova
EA200100428A1 (ru) Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты)
MY119238A (en) 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
DE68905979D1 (de) Antidepressive n-substitierte nikotinamid-verbindungen.
HRP20031098B1 (en) Beta-amino tetrahydroimidazo (1,2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
HUP9802822A2 (hu) Halogén-benzimidazol-származékok, intermedierjeik, előállításuk és a vegyületeket hatóanyagként tartalmazó mikrobicid készítmények
YU46787B (sh) Derivati heteroaril 3-okso-propan-nitrila i postupak za njihovo dobijanje
DK0759027T3 (da) Bicykliske amidinderivater som inhibitorer af nitrogenoxidsynthetase
TW200510320A (en) Aminoquinoline derivatives and their use as adenosine A3 ligands
CO5690577A2 (es) Derivados de imidazoquinolina como ligandos receptores de adenosina a3
AR036074A1 (es) Derivados de aminoquinolina, las composiciones farmaceuticas que los contienen, el uso de los mismos para la preparacion de una composicion farmaceutica, un procedimiento para su preparacion y los intermediarios empleados en dicho procedimiento de preparacion
HUP9702393A2 (hu) bisz(2-Halogén-etil)-amino-fenil szubsztituált distamycinszármazékok, tumorellenes és vírusellenes hatóanyagok
DE69910568D1 (de) Furopyridinderivate und ihre therapeutische verwendung
DE69928951D1 (de) 2,3-dihydro-1h-isoindol-derivate verwendbar als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)
DK156477C (da) Analogifremgangsmaade til fremstilling af heterocyclisk substituerede tetrahydro-thiopyran- eller -thiophen-carbothio-amid-derivater
MXPA03000887A (es) Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa.
DK87383A (da) Basisk substituerede 4-phenyl-4,5,6,7-tetrahydrothieno(2,3-c)pyridiner, fremgangsmaade til deres fremstilling samt farmaceutiske praeparater indeholdende disse forbindelser
MX9709465A (es) Derivados de bencimidazol 2-sustituidos como inhibidores de la proliferacion de celulas del musculo liso.
EP1145713A4 (en) Telomerase inhibitors
ATE51224T1 (de) Chinolon-inotropische mittel.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20120412

Year of fee payment: 11

B1PR Patent granted
PBON Lapse due to non-payment of renewal fee

Effective date: 20130530